We are live on ! Find out more
D.E. Shaw & Co

D.E. Shaw & Co Portfolio holdings

AUM $166B
1-Year Est. Return 43.98%
 

D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.

This Fund
S&P 500
This Quarter Est. Return
+8.35%
1 Year Est. Return
+43.98%
3 Year Est. Return
+138.44%
5 Year Est. Return
+164.23%
10 Year Est. Return
+713.02%
AUM
$116B
AUM Growth
+$12.3B
Cap. Flow
-$2.57B
Cap. Flow %
-2.21%
Top 10 Hldgs %
9.91%
Holding
5,208
New
1,193
Increased
1,491
Reduced
1,580
Closed
489

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$672M
2
MRK icon
Merck
MRK
+$476M
3
META icon
Meta Platforms (Facebook)
META
+$392M
4
MCD icon
McDonald's
MCD
+$372M
5
WFC icon
Wells Fargo
WFC
+$357M

Sector Composition

Rank Sector Weight
1 Technology 15.62%
2 Consumer Discretionary 9.84%
3 Healthcare 7.45%
4 Communication Services 7.19%
5 Financials 5.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CMCM
4426
Cheetah Mobile
CMCM
$88.8M
$72K ﹤0.01%
6,060
-12,803
-68% -$144K
LCTX icon
4427
Lineage Cell Therapeutics
LCTX
$257M
$72K ﹤0.01%
+25,219
New +$65.3K
FVT.WS
4428
DELISTED
Fortress Value Acquisition Corp. III Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
FVT.WS
$71K ﹤0.01%
59,415
GSMGW
4429
DELISTED
Cheer Holding, Inc. Warrant expiring 2/13/2025
GSMGW
$70K ﹤0.01%
498,473
-2,300
-0.5% -$322
SCOBW
4430
DELISTED
ScION Tech Growth II Warrants
SCOBW
$69K ﹤0.01%
+75,000
New +$57.5K
GNSS icon
4431
Genasys
GNSS
$75.6M
$67K ﹤0.01%
+12,301
New +$75.1K
LVRAW
4432
DELISTED
Levere Holdings Corp. Warrant
LVRAW
$67K ﹤0.01%
+66,666
New +$64.6K
PDOT.WS
4433
DELISTED
Peridot Acquisition Corp. II Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
PDOT.WS
$67K ﹤0.01%
+60,000
New +$60.5K
ASAXW
4434
DELISTED
Astrea Acquisition Corp. Warrant
ASAXW
$67K ﹤0.01%
+100,000
New +$54.1K
GALT icon
4435
Galectin Therapeutics
GALT
$229M
$66K ﹤0.01%
20,607
-25,168
-55% -$89.6K
PHAS
4436
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$66K ﹤0.01%
+17,674
New +$58.8K
NWG icon
4437
NatWest
NWG
$71.5B
$65K ﹤0.01%
21,375
RMGCW
4438
DELISTED
RMG Acquisition Corp. III Warrant
RMGCW
$65K ﹤0.01%
+50,000
New +$51.8K
CAS.WS
4439
DELISTED
Cascade Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one share of Class
CAS.WS
$65K ﹤0.01%
64,699
AVTX icon
4440
Avalo Therapeutics
AVTX
$976M
$63K ﹤0.01%
+7
New +$58.6K
GGB icon
4441
Gerdau
GGB
$9.44B
$63K ﹤0.01%
+13,395
New +$65.6K
JWSM.WS
4442
DELISTED
Jaws Mustang Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
JWSM.WS
$63K ﹤0.01%
+50,000
New +$57.4K
AAC.WS
4443
DELISTED
Ares Acquisition Corporation Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
AAC.WS
$63K ﹤0.01%
+50,000
New +$52.7K
AONCW
4444
DELISTED
American Oncology Network, Inc. Warrant
AONCW
$58K ﹤0.01%
+62,164
New +$49.6K
VEON icon
4445
VEON
VEON
$3.53B
$57K ﹤0.01%
+1,254
New +$55.3K
GIGGW
4446
DELISTED
GigCapital4, Inc. Warrant
GIGGW
$57K ﹤0.01%
+50,000
New +$46.7K
SPKBW
4447
DELISTED
Silver Spike Acquisition Corp II Warrant
SPKBW
$56K ﹤0.01%
+41,666
New +$48.3K
RKTA.WS
4448
DELISTED
Rocket Internet Growth Opportunities Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
RKTA.WS
$55K ﹤0.01%
+41,666
New +$49K
SWBK.WS
4449
DELISTED
Switchback II Corporation Warrants, exercisable for one share of Class A Ordinary Share
SWBK.WS
$54K ﹤0.01%
39,826
+14,826
+59% +$22K
AGGRW
4450
DELISTED
Agile Growth Corp Warrant
AGGRW
$53K ﹤0.01%
+55,555
New +$43.8K

Similar funds

D.E. Shaw & Co's Q2 2021 Portfolio in Review

As of Q2 2021, D.E. Shaw & Co held 5,208 positions worth $116B, up 12% from $104B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.

D.E. Shaw & Co's Q2 2021 filing shows 1,193 new, 1,491 increased, 1,580 reduced and 489 closed positions. Its largest new stake was Weatherford International: 4,894,906 shares worth $89.1M. The largest sale was Microsoft, an estimated $672M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • D.E. Shaw & Co's largest Q2 2021 buy was Weatherford International: 4,894,906 shares worth $89.1M.
  • D.E. Shaw & Co added most to Just Eat Takeaway.com N.V. American Depositary Shares in Q2 2021, an estimated $700M increase.
  • D.E. Shaw & Co's biggest Q2 2021 reduction was Microsoft, cutting an estimated $672M.
  • D.E. Shaw & Co fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $131M.
  • D.E. Shaw & Co's ten largest holdings make up 9.9% of its $116B portfolio in Q2 2021.
  • D.E. Shaw & Co opened 1,193 new positions and closed 489 in Q2 2021.
  • D.E. Shaw & Co's portfolio value rose 12% quarter-over-quarter to $116B.

Based on D.E. Shaw & Co's 13F filing for Q2 2021, filed 16 Aug 2021.